Last Price$4.3(4.0%)
Market Cap$211.4B
LTM Free Cash Flow per Share
($1.0)
5Y avg
($0.7)
Biotechnology industry
median
($1.4)
Stock quality & Intrinsic value
6/10
(1.0%) overvalued
Silence Therapeutics plc Free Cash Flow per Share
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
| Free Cash Flow per Share | ($0.4) | $0.2 | ($1.5) | ($1.1) |
Overvalued or undervalued?
Check the intrinsic value for SLN
and see if it's the right time to invest.
Silence Therapeutics plc (SLN) Free Cash Flow per Share comparison analysis
General
LTM Free Cash Flow per Share
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Silence Therapeutics plcSLN
($1.0)
45.7%
(6.7%)
(170.5%)
Median Peer Set
$0.5
18.9%
(47.6%)
0.4%
Regeneron Pharmaceuticals, Inc.REGN
$33.3
8.3%
10.4%
31.1%
United Therapeutics CorporationUTHR
$24.3
23.6%
25.7%
41.5%
Novo Nordisk A/SNVO
$15.7
24.9%
142.8%
34.8%
BioNTech SEBNTX
$4.1
(77.4%)
(89.7%)
24.4%
Incyte CorporationINCY
$1.1
14.8%
(94.0%)
0.8%
Summit Therapeutics Inc.SMMT
($0.2)
N/A
(68.7%)
N/A
Alnylam Pharmaceuticals, Inc.ALNY
($0.3)
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals IncorporatedVRTX
($3.1)
11.7%
N/A
(4.9%)
argenx SEARGX
($3.6)
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
($9.6)
73.7%
(56.5%)
(35.9%)
SLN key stats
USD
GBP
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.3 0.0% | 0.9 217.9% | 3.6 287.2% | 8.1 125.8% | 4.1 (49.5%) | 2.7 (34.1%) | 3.7 35.5% | 1.1 (69.6%) | 0.3 (76.8%) | 0.2 (29.1%) | 0.0 (86.5%) | 0.0 (100.0%) | 1.0 0.0% | 0.0 (98.0%) | 0.0 (100.0%) | 0.3 0.0% | 7.0 2,158.4% | 17.1 142.7% | 21.7 26.8% | 31.6 45.7% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 9.7 | 12.4 | 7.9 | 9.0 | 5.4 | 5.4 | 8.8 | 14.6 | 10.9 | 11.8 | 10.2 | 13.0 | 0.0 | 4.8 | 10.3 | 13.5 | 12.8 |
% margin | 0.3 100.0% | 0.9 100.0% | 3.6 100.0% | (1.6) (19.7%) | (8.3) (203.8%) | (5.2) (194.4%) | (5.3) (146.0%) | (4.3) (384.3%) | (5.1) (1,972.4%) | (8.7) (4,727.4%) | (14.6) (59,126.7%) | (10.9) 0.0% | (10.8) (1,031.3%) | (10.2) (49,543.8%) | (13.0) 0.0% | 0.3 100.0% | 2.2 31.3% | 6.8 39.9% | 8.2 37.8% | 18.7 59.3% |
| Operating Expenses | 6.5 | 8.0 | 11.4 | 9.7 | 6.1 | 6.6 | 7.9 | 4.2 | 9.5 | 14.4 | 20.0 | 14.9 | 17.2 | 18.6 | 27.5 | 29.3 | 48.2 | 69.8 | 68.3 | 80.4 |
| Research & Development Expenses (R&D) | 3.1 | 3.0 | 5.9 | 9.7 | 12.4 | 7.9 | 9.0 | 5.4 | 5.4 | 8.8 | 14.6 | 10.9 | 11.8 | 10.2 | 13.0 | 17.0 | 25.9 | 42.3 | 44.0 | 54.7 |
| Selling, General & Administrative Expenses (SG&A) | 3.4 | 5.0 | 5.6 | 10.0 | 6.1 | 5.0 | 7.9 | 4.2 | 4.1 | 5.5 | 5.4 | 4.1 | 5.4 | 8.3 | 14.5 | 12.3 | 18.0 | 27.5 | 24.3 | 25.7 |
% margin | (6.2) (2,118.2%) | (7.1) (765.8%) | (7.9) (219.2%) | (11.6) (143.0%) | (14.4) (352.7%) | (11.8) (438.4%) | (13.4) (365.9%) | (9.3) (833.7%) | (41.7) (16,143.6%) | (14.2) (7,753.8%) | (20.0) (80,846.7%) | (14.9) 0.0% | (16.1) (1,546.2%) | (18.5) (89,943.8%) | (27.5) 0.0% | (29.0) (9,317.2%) | (46.0) (654.3%) | (63.0) (369.0%) | (60.1) (277.7%) | (61.7) (195.5%) |
| Interest Income | 0.2 | 0.5 | 0.6 | 1.1 | 0.7 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.2 | 0.3 | 2.1 | 0.3 | 0.1 | 0.0 | 0.2 | 0.0 | 0.3 | 1.8 |
| Interest Expense | 0.1 | 0.0 | 0.0 | 0.0 | (0.1) | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.4 | 0.0 | 0.1 | 0.0 |
| Pre-tax Income | (6.1) | (6.6) | (7.3) | (10.5) | (13.8) | (11.8) | (13.6) | (9.2) | (41.7) | (14.1) | (19.7) | (14.4) | (14.1) | (4.9) | (27.4) | (29.2) | (46.3) | (63.1) | (58.6) | (62.6) |
% effective tax rate | (0.6) 10.6% | (0.1) 1.4% | (0.2) 2.9% | (0.3) 2.6% | (0.7) 4.8% | (0.1) 0.5% | 0.2 (1.6%) | (0.1) 0.9% | (0.0) 0.1% | (0.1) 0.8% | (1.5) 7.4% | (4.3) 29.5% | (2.6) 18.5% | (2.8) 57.1% | (2.8) 10.3% | (4.2) 14.4% | (4.5) 9.7% | (8.9) 14.1% | (8.5) 14.5% | (8.8) 14.0% |
% margin | (5.4) (1,859.1%) | (6.5) (704.3%) | (7.0) (196.5%) | (10.2) (126.2%) | (13.8) (336.6%) | (11.7) (433.6%) | (13.6) (371.7%) | (9.2) (826.7%) | (41.7) (16,125.2%) | (14.1) (7,694.0%) | (18.3) (73,920.0%) | (10.2) 0.0% | (11.4) (1,096.1%) | (2.1) (10,112.5%) | (24.6) 0.0% | (25.0) (8,025.4%) | (41.8) (594.0%) | (54.2) (317.4%) | (50.1) (231.4%) | (53.8) (170.5%) |
| EPS | (34.04) | (16.07) | (11.11) | (13.19) | (17.23) | (13.03) | (7.33) | (2.95) | (6.51) | (0.95) | (1.09) | (0.47) | (0.49) | (0.09) | (1.05) | (1.00) | (1.53) | (1.83) | (1.56) | (1.45) |
| Diluted EPS | (34.04) | (16.07) | (11.11) | (13.19) | (17.23) | (13.03) | (7.33) | (2.95) | (6.51) | (0.95) | (1.09) | (0.47) | (0.49) | (0.09) | (1.05) | (1.00) | (1.53) | (1.83) | (1.56) | (1.45) |
% margin | (5.9) (2,011.3%) | (6.2) (671.5%) | (6.6) (184.2%) | (10.6) (131.4%) | (13.8) (336.8%) | (11.1) (413.1%) | (12.6) (345.3%) | (8.7) (780.8%) | (8.4) (3,255.8%) | (13.7) (7,500.0%) | (19.4) (78,633.3%) | (14.7) 0.0% | (15.7) (1,506.0%) | (4.3) (20,793.8%) | (26.9) 0.0% | (28.5) (9,161.9%) | (45.6) (648.5%) | (62.5) (365.9%) | (59.2) (273.6%) | (61.9) (196.2%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Silence Therapeutics plc's Free Cash Flow per Share?
As of today, Silence Therapeutics plc's last 12-month Free Cash Flow per Share is ($1.0), based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Silence Therapeutics plc's Free Cash Flow per Share growth rate?
Over the last year, Silence Therapeutics plc's Free Cash Flow per Share growth was (13.7%). The average annual Free Cash Flow per Share growth rates for Silence Therapeutics plc have been 5.1% over the past three years, N/A over the past five years.
3) Is Silence Therapeutics plc's Free Cash Flow per Share growth rate Good?
Over the last year, Silence Therapeutics plc's Free Cash Flow per Share growth was (13.7%), which is lower than industry growth of (0.2%). It indicates that Silence Therapeutics plc's Free Cash Flow per Share growth is Bad.